These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39066405)

  • 1. Inequitable Distribution of Global Economic Benefits from Pneumococcal Conjugate Vaccination.
    Niyibitegeka F; Russell FM; Jit M; Carvalho N
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries.
    Herlihy N; Hutubessy R; Jit M
    Health Aff (Millwood); 2016 Feb; 35(2):227-34. PubMed ID: 26858374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries.
    Banerjee P; Huber J; Denti V; Sauer M; Weeks R; Dhaliwal BK; Shet A
    Glob Health Action; 2023 Dec; 16(1):2281065. PubMed ID: 38084434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal conjugate vaccine implementation in middle-income countries.
    Tricarico S; McNeil HC; Cleary DW; Head MG; Lim V; Yap IKS; Wie CC; Tan CS; Norazmi MN; Aziah I; Cheah ESG; Faust SN; Jefferies JMC; Roderick PJ; Moore M; Yuen HM; Newell ML; McGrath N; Doncaster CP; Kraaijeveld AR; Webb JS; Clarke SC
    Pneumonia (Nathan); 2017; 9():6. PubMed ID: 28702308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal conjugate vaccine--a health priority.
    Zar HJ; Madhi SA
    S Afr Med J; 2008 Jun; 98(6):463-7. PubMed ID: 18683380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerating Pneumococcal Conjugate Vaccine introductions in Indonesia: key learnings from 2017 to 2022.
    Athiyaman A; Herliana P; Anartati A; Widyastuti N; Yosephine P; Tandy G; Karolina S
    Infect Dis Poverty; 2023 Nov; 12(1):107. PubMed ID: 38017524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study.
    Wang J; Wang Y; Xu R; Zhang T; Jiang Y; Wang Y; Wang Y; Du Y; Sun W; Deng K; Yang W; Wang Z; Feng L; Wang C
    Infect Dis Poverty; 2023 Dec; 12(1):110. PubMed ID: 38037092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India.
    Ghia CJ; Horn EK; Rambhad G; Perdrizet J; Chitale R; Wasserman MD
    Infect Dis Ther; 2021 Dec; 10(4):2271-2288. PubMed ID: 34313958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status of New Vaccine Introduction - Worldwide, September 2016.
    Loharikar A; Dumolard L; Chu S; Hyde T; Goodman T; Mantel C
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1136-1140. PubMed ID: 27764083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
    Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
    BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Pneumococcal Conjugate Vaccine Administration in Pediatric Older Age Groups in Low and Middle Income Countries: A Systematic Review.
    Bonner K; Welch E; Elder K; Cohn J
    PLoS One; 2015; 10(8):e0135270. PubMed ID: 26332848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis.
    Chen C; Cervero Liceras F; Flasche S; Sidharta S; Yoong J; Sundaram N; Jit M
    Lancet Glob Health; 2019 Jan; 7(1):e58-e67. PubMed ID: 30554762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.